Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Any day now, Cardiff (NASDAQ: CRDF ) may announce objective response rate data of its Phase 2 trial for the first-line treatment of RAS-mutated metastatic colorectal cancer. This data has been awaited because of I am working in the financial sector. My areas of interest are technology, biotech, pharmaceutical companies, banks and a bit of shipping when an actionable trade passes on my radar. Analyst's Disclosure: I/we have a beneficial long position in the shares of CRDF either through stock ownership, opti ...